

09/040103

Set Name Query
side by side

Hit Count Set Name
result set

DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR

<u>L8</u>	L6 and non near primate near5 (cell or cells) and human near5 serum near10 (undiluted or 100\$ or fully)
<u>L7</u>	L6 and non near primate near5 (cell or cells)
<u>L6</u>	retrovir\$ near5 vector\$ and serum near5 resist\$ near5 retrovir\$
<u>L5</u>	l2 and (lack\$ or absent) near5 endogenous near5 retrovir\$
<u>L4</u>	L2 and moloney near10 (hybridiz\$ or complement\$)
<u>L3</u>	retrovir\$ near5 vector\$ and human near5 serum near3 resist\$ and non near primate near5 (cell or cells) and (Mpf or MDOK or Mv near 1 near Lu)
<u>L2</u>	retrovir\$ near5 vector\$ and human near5 serum near3 resist\$ and non near primate near5 (cell or cells)
<u>L1</u>	retrovir\$ near5 vector\$ and human near5 serum near3 resist\$

3. Search near 10
for (element 1)

0	<u>L8</u>
8	<u>L7</u>
30	<u>L6</u>
0	<u>L5</u>
1	<u>L4</u>
1	<u>L3</u>
13	<u>L2</u>
55	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 30 of 30 returned.**

-
- ☐ 1. 20030157718 . 26 Oct 01. 21 Aug 03. Expression of heterologous genes from an IRES translational cassette in retroviral vectors. Pedersen, Finn Skou, et al. 435/456; 435/235.1 435/320.1 435/6 C12Q001/68 C12N007/00 C12N015/867.
-
- ☐ 2. 20030157070 . 22 Oct 01. 21 Aug 03. High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations. Jolly, Douglas J.. 424/93.21; 435/372 435/455 435/456 A61K048/00 C12N015/867 C12N005/08.
-
- ☐ 3. 20030118551 . 13 Jul 01. 26 Jun 03. Modified viral surface proteins for binding to extracellular matrix components. Hall, Frederick L., et al. 424/93.2; 435/320.1 435/456 530/350 536/23.72 A61K048/00 C07H021/02 C12N015/867 C07K014/47.
-
- ☐ 4. 20030012769 . 21 Dec 01. 16 Jan 03. Non-primate lentiviral vectors and packaging systems. Poeschla, Eric M., et al. 424/93.2; 435/235.1 435/456 514/44 A61K048/00 C12N015/867 C12N007/00.
-
- ☐ 5. 20020045247 . 08 May 97. 18 Apr 02. METHODS FOR THE PREPARATION OF RETROVIRAL PARTICLES AND CELL LINES DEFICIENT IN THE ALPHA-GALACTOSYL EPI TOPE. ROTHER, RUSSELL P., et al. 435/320.1; C12N015/09 C12N015/00 C12N015/63 C12N015/70 C12N015/74.
-
- ☐ 6. 20010016347 . 17 Apr 01. 23 Aug 01. Non-primate lentiviral vectors and packaging systems. Poeschla, Eric M., et al. 435/235.1; C12N007/01.
-
- ☐ 7. 6555107 . 17 Apr 01; 29 Apr 03. Lentiviral nucleic acids and uses thereof. Poeschla; Eric M., et al. 424/93.2; 424/93.1 424/93.6 435/235.1 435/320.1 435/325 435/366 435/455 435/456 435/457 536/23.1 536/23.72 536/24.1 536/24.5. A61K048/00 C12N015/867 C12N015/63 C12N005/10 C07H021/04.
-
- ☐ 8. 6503501 . 13 Aug 99; 07 Jan 03. Targetable vector particles. Anderson; W. French, et al. 424/93.2; 424/93.1 424/93.6 435/320.1 435/455 435/456. A61K048/00 C12N015/867 C12N015/63.
-
- ☐ 9. 6475756 . 21 Jul 00; 05 Nov 02. Development of viruses resistant to inactivation by the human complement system. Wirth; Dagmar, et al. 435/69.7; 424/192.1 435/5 536/23.4. C12P021/04 C12Q001/70 A61K039/00 C07H021/04.
-
- ☐ 10. 6432709 . 30 Nov 95; 13 Aug 02. Encapsulation cell lines and expression vectors for transcomplementation of defective retroviral vectors. Cohen-Haguenaer; Odile. 435/350; 435/320.1 435/325 435/352 435/363 435/366 435/455 435/69.1. C12N005/10 C12N015/85 C12N015/63.
-
- ☐ 11. 6329199 . 13 Aug 99; 11 Dec 01. Retroviral vectors produced by producer cell lines resistant to lysis by human serum. Pensiero; Michael, et al. 435/320.1; 435/325 435/352 435/357 435/363 435/366 435/368 435/369 435/371 435/455 435/456 536/23.1 536/23.72 536/24.1. C12N015/867 C12N005/10 C12N015/64 C07H021/04.
-
- ☐ 12. 6312948 . 03 Nov 99; 06 Nov 01. Retroviral vector for the transfer and expression of genes for therapeutic purposes in eukaryotic cells. Cohen-Haguenaer; Odile. 435/320.1; 435/235.1 435/440 435/455 435/456 536/24.1. C12N015/63 C12N015/86.
-

- ☐ 13. 6248725 . 23 Feb 99; 19 Jun 01. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction. Alison; Malcom R., et al. 514/44; 424/198.1 424/199.1 424/9.1 424/9.2 435/320.1 435/455 435/456 800/8 800/9. A01N043/04 A61K031/70 C12N015/00 C12N015/09 C12N015/63.
-
- ☐ 14. 6168916 . 21 Oct 98; 02 Jan 01. Host adaptation of retroviral vectors. Kingsman; Alan John, et al. 435/5; 435/235.1 435/236 435/237 435/320.1 435/325 435/455 435/456 435/6 435/7.1. C12N005/10 C12N015/867 C12N015/64 C12Q001/70.
-
- ☐ 15. 6165715 . 22 Jun 98; 26 Dec 00. Expression systems. Collins; Mary Katherine Levinge, et al. 435/6; 435/320.1 435/325 435/354 435/366 435/371 435/372.1 435/455 435/456 435/69.1 536/23.1 536/24.1. C12Q001/68 C12N005/10 C12N015/86 C12N015/63.
-
- ☐ 16. 6136598 . 08 May 98; 24 Oct 00. Mus dunni endogenous retroviral packaging cell lines. Miller; A. Dusty, et al. 435/325; 435/355. C12N005/10.
-
- ☐ 17. 5985655 . 07 Jun 95; 16 Nov 99. Targetable vector particles. Anderson; W. French, et al. 435/320.1; 435/325. C12N015/63.
-
- ☐ 18. 5952225 . 17 Aug 95; 14 Sep 99. Retroviral vectors produced by producer cell lines resistant to lysis by human serum. Pensiero; Michael, et al. 435/352; 435/320.1 435/325 435/366 435/369 435/371. C12N005/10 C12N015/86.
-
- ☐ 19. 5910434 . 15 Dec 95; 08 Jun 99. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant. Rigg; Richard J., et al. 435/6; 435/325 435/350 435/357 435/363 435/366 435/465 435/7.1 435/7.72. C12N005/10 C12N015/63 C12N015/67.
-
- ☐ 20. 5871997 . 06 Mar 95; 16 Feb 99. Methods and compositions for protecting retroviral vector particles and producer cells from inactivation by complement via reduction of the expression or recognition of galactose alpha (1,3) galactosyl epitopes. Rother; Russell P., et al. 435/235.1; 435/238 435/239 435/325. C12N007/00 C12N007/06 C12N007/02 C12N005/00.
-
- ☐ 21. 5869035 . 13 Nov 96; 09 Feb 99. Methods and compositions for inducing complement destruction of tissue. Link, Jr.; Charles J., et al. 424/93.7; 424/277.1 424/93.21 435/320.1 514/44. A01N043/04 A01N063/00 A61K039/00 C12N015/00.
-
- ☐ 22. 5681746 . 30 Dec 94; 28 Oct 97. Retroviral delivery of full length factor VIII. Bodner; Mordechai, et al. 435/350; 435/320.1 435/366 435/371 536/23.5. C12N005/00 C12N015/63 C07H021/04.
-
- ☐ 23. WO 9947659 A1 . 16 Mar 99. 23 Sep 99. USE OF HUMAN SERUM RESISTANT VECTOR PARTICLES AND CELL LINES FOR HUMAN GENE THERAPY. MASON, JAMES M. C12N015/00; A01N063/00.
-
- ☐ 24. WO 9604934 A1 . 17 Aug 95. 22 Feb 96. RETROVIRAL VECTORS PRODUCED BY PRODUCER CELL LINES RESISTANT TO LYSIS BY HUMAN SERUM. PENSIERO, MICHAEL, et al. A61K048/00; C12N005/00 C12N005/08 C12N005/10 C12N005/22 C12N015/00 C12N015/86.
-
- ☐ 25. WO 9325698 A1 . 14 May 93. 23 Dec 93. VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM. ANDERSON, W FRENCH, et al. C12P021/06; C12N015/00 C12N007/00 C12N005/00 C07K003/00 C07K013/00 C07K015/00.
-
- ☐ 26. US 6329199 B1 . Retroviral vectors resistant to inactivation by human serum, useful to

introduce genes into animal cells especially in gene therapy, are produced in a cell line resistant to lysis by human serum. COLLINS, M K L, et al. C07H021/04 C12N005/10 C12N015/64 C12N015/867.

☐ 27. WO 9947659 A1 AU 9931875 A . Production of human serum-resistant retroviral vector particles, used particularly for gene therapy, , e.g. for treating inherited and acquired diseases. MASON, J M. A01N063/00 C12N015/00.

☐ 28. US 5952225 A . Retroviral vectors resistant to lysis by human serum. COLLINS, M K L, et al. C12N005/10 C12N015/86.

☐ 29. WO 9604934 A1 EP 769968 A1 EP 769968 A4 JP 10507905 W . Retroviral vectors for use in gene therapy - which are resistant to inactivation by human serum and are produced by cells resistant to lysis by human serum.. COLLINS, M K L, et al. A61K031/70 A61K035/76 A61K038/00 A61K038/21 A61K038/22 A61K038/28 A61K038/46 A61K039/395 A61K048/00 C12N005/00 C12N005/08 C12N005/10 C12N005/22 C12N007/00 C12N015/00 C12N015/09 C12N015/86.

☐ 30. WO 9325698 A1 JP 09507741 W EP 644946 A1 EP 644946 A4 . New retroviral vector resistant to inactivation by serum - for direct gene transfer, includes p15E protein mutated to inhibit binding of complement. ANDERSON, W, et al. C07K003/00 C07K013/00 C07K014/15 C07K015/00 C12N005/00 C12N005/10 C12N007/00 C12N015/00 C12N015/09 C12P021/06.

Generate Collection

Print

Terms	Documents
retrovir\$ near5 vector\$ and serum near5 resist\$ near5 retrovir\$	30

[Previous Page](#)

[Next Page](#)



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)